The founder BRCA2 c.8756delG PTV was detected in 1.01% of breast cancer cases (n = 10/990) and 0.09% of controls (n = 1/1,094) which corresponds to more than half of the BRCA2 PTVs observed among cases (55.56%, n = 10/18) and the only BRCA2 PTV identified among controls. This evidence concerns the gene BRCA2 and breast cancer.